Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9870
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryden, L. | - |
dc.contributor.author | Armstrong, P. | - |
dc.contributor.author | Cleland, J. | - |
dc.contributor.author | Horowitz, J. | - |
dc.contributor.author | Massie, B. | - |
dc.contributor.author | Packer, M. | - |
dc.contributor.author | Poole-Wilson, P. | - |
dc.date.issued | 2000 | - |
dc.identifier.citation | European Heart Journal, 2000; 21(23):1967-1978 | - |
dc.identifier.issn | 0195-668X | - |
dc.identifier.issn | 1522-9645 | - |
dc.identifier.uri | http://hdl.handle.net/2440/9870 | - |
dc.description.abstract | <h4>Aims</h4>An analysis was designed to determine whether chronic heart failure patients at high cardiovascular risk benefited to the same extent from high-dose lisinopril as the whole ATLAS population.<h4>Methods and results</h4>A retrospective analysis was performed on high-risk heart failure patients in the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial (total number of patients 3164) comparing highdose (32.5-35 mg. day(-1)) vs low-dose (2.5-5 mg. day(-1)) lisinopril for a median of 46 months. These high-risk patients included those with hypotension, hyponatraemia, compromised renal function, the elderly and patients with diabetes mellitus at baseline. In the whole study population, high-dose lisinopril led to a trend in risk reduction of all-cause mortality (primary end-point P=0.128) and a significant risk reduction in all-cause mortality plus hospitalization (principal secondary end-point P=0.002). Subgroup analyses were performed for these end-points. There were no consistent interactions between age, baseline sodium, creatinine or potassium values, and treatment effect. Diabetics showed a beneficial response to high-dose therapy that was at least as good as that in non-diabetics. The underlying higher morbidity/mortality rates in diabetics mean that high-dose lisinopril has potential for a larger absolute clinical impact in these patients.<h4>Conclusion</h4>Long-term high-dose lisinopril was as effective and well-tolerated in high-risk patients, including those with diabetes mellitus, as for the ATLAS study population as a whole. | - |
dc.language.iso | en | - |
dc.publisher | W B Saunders Co Ltd | - |
dc.source.uri | http://dx.doi.org/10.1053/euhj.2000.2311 | - |
dc.subject | Humans | - |
dc.subject | Diabetes Complications | - |
dc.subject | Chronic Disease | - |
dc.subject | Lisinopril | - |
dc.subject | Angiotensin-Converting Enzyme Inhibitors | - |
dc.subject | Hospitalization | - |
dc.subject | Drug Administration Schedule | - |
dc.subject | Survival Analysis | - |
dc.subject | Retrospective Studies | - |
dc.subject | Databases, Factual | - |
dc.subject | Aged | - |
dc.subject | Aged, 80 and over | - |
dc.subject | Middle Aged | - |
dc.subject | New York | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.subject | Heart Failure | - |
dc.subject | Randomized Controlled Trials as Topic | - |
dc.title | Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1053/euhj.2000.2311 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Horowitz, J. [0000-0001-6883-0703] | - |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.